LYELL IMMUNOPHARMA INC (LYEL)
Health Care · Biotechnology / Cell Therapy · NASDAQ
Lyell Immunopharma is developing next-generation, engineered CAR T-cell therapies designed to provide durable, curative responses in hematologic and solid tumor cancers.
What LYELL IMMUNOPHARMA INC does
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation autologous chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies and solid tumors. The company engineers patient immune cells with proprietary enhancements, including anti-exhaustion technologies and manufacturing protocols that enrich for T-cells with stem-like features, to improve antitumor activity. Its lead candidate, ronde-cel, is in pivotal trials for large B-cell lymphoma (LBCL), while LYL273 is being investigated for metastatic colorectal cancer.
Recent developments
In August 2026, the company reported positive updated safety data for ronde-cel and LYL273, with ronde-cel on track for 2027 BLA submission. The LYL273 Phase 1 trial was amended to a Phase 1/2 design to facilitate expansion into a potential pivotal Phase 2 trial.
From LYELL IMMUNOPHARMA INC's filing of 2026-08-06.
Themes: CAR T-cell therapy, hematologic malignancies, solid tumor therapy, cell manufacturing, clinical-stage biotech
Fundamentals
- Price$8.79 as of 2026-10-08 close
- Market cap$215M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return-51.9% 2025-10-08 close $18.26 → 2026-10-08 close $8.79
- P/En/a negative earnings
- Net margin-762355.6% FY2025, SEC XBRL
- ROE-110.6% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)-52.3% as of 2026-09-03
- Revenue CAGR (3y)-92.5% SEC XBRL
- Beta1.31 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How LYEL compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How LYELL IMMUNOPHARMA INC looks technically
LYELL IMMUNOPHARMA INC (LYEL) is trading 53.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 89 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 25, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 80.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 53.5% below its 200-day average, the long-term trend line — a long-term downtrend | -53.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.60 | $12.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $18.90 | $18.90 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 50 calendar days ago — the swings before that are what the structure reading is measured on | 50 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 17.15. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 89 trading days ago — a "death cross", a bearish long-term signal | 89 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with sellers in control | 42.5 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 25, in oversold territory (below 30) | 25.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($8.21 to $11.22) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 19.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.00 | $45.00 |
|---|---|---|
| From the 52-week high | it is 80.5% below its 52-week high (its highest price of the past year) | -80.5% |
| Above the 52-week low | it is 7.1% above its 52-week low (its lowest price of the past year) | +7.1% |
| Below the 52-week high | it is 80.5% below its highest point of the past year | 80.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $396.80 (set on 2021-09-07) | $396.80 |
| Given back of the 52-week move | over the past year its closes ranged ($8.56 to $38.60), and it has recovered essentially none of its fall from last year’s high — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $27.12 to $28.09. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.8% |
| From the all-time high | it is 97.8% below its all-time high | -97.8% |
| Nearest price level | it is trading 1.7% below a resistance level at $8.94 — a price it turned at three times since 2025-05-14, most recently on 2025-07-15. Since 2024-10-08 it has 0 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.7% |
| All-time low | its lowest closing price on record is $7.65 (set on 2025-06-02) | $7.65 |
| Above the all-time low | it is 14.9% above its all-time low | +14.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6555 between its high and its low — about 7.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6555 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.19 and $12.03 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.19 – $10.11 – $12.03 |
| Typical daily range (% of price) | its price moves about 7.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 15.4 daily ranges below its 200-day average price (53.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 15.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.51× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a hammer | 3 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 36.1 percentage points (the stock lost 35.0% while the market gained 1.0%) | -36.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 46.7 percentage points (the stock lost 42.9% while the market gained 3.8%) | -46.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 76.9 percentage points (the stock lost 59.5% while the market gained 17.5%) | -76.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 66.8 percentage points (the stock lost 51.9% while the market gained 15.0%) | -66.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 39% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.5% of the share price. | -38.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 47% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $16.52 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -46.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 29% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $12.34 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -28.8% |
Price levels it has turned at before
LYEL last closed at $8.79 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 11 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.94 | Resistance | 1.7% above the last close | turned there three times · 2025-05-14 to 2025-07-15 |
| $10.22 | Resistance | 16.3% above the last close | turned there three times · 2025-02-11 to 2025-05-01 |
| $11.05 | Resistance | 25.7% above the last close | turned there twice · 2025-01-14 to 2025-01-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $17.15.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 31 trading days, since 2026-08-26.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.63 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$37.88 range $12.00 – $49.00; median $41.50
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LYEL
- Consensus EPS estimate-$1.88 next reporting period, as of 2026-10-03
- Estimate change, 30 days$0.00 from -$1.88, on 2026-08-29, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has no approved products and has never generated revenue, leading to substantial and continuing net losses.","Requires significant additional capital to fund clinical trials and future commercialization, creating risks of potential dilution.","Failure to successfully develop, manufacture, or receive regulatory approval for its pipeline candidates would significantly harm the business."]
What changed in the latest 10-Q
AI-assisted comparison of LYEL's 10-Q filed 2026-05-06 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Annual Report on Form 10-K filed March 12, 2026 (newer filing uses 2025 year-end data)
- Specification that PiNACLE is 'a single-arm clinical trial that is a seamless expansion of the 3L+ cohort in the Phase 1/2 trial'
- Statement that PiNACLE trial 'is expected to report additional data in the second half of 2026 and pivotal data in mid-2027, with submission of a Biologics License Application expected to follow in 2027'
- Description of PiNACLE-H2H as 'first-of-its-kind Phase 3 head-to-head CAR T-cell therapy randomized controlled trial'
- Specification that LYL273 acquisition was 'in November 2025'
- Reference to 'Innovative Cellular Therapeutics Holdings Limited and Innovative Cellular Therapeutics (collectively, ICT)'
- Specification that LYL273 data cutoff date was 'October 28, 2025'
- Statement that LyFE (LyFE Manufacturing Center TM) is 'capable of providing clinical trial material for our ongoing clinical trials, as well as for commercial launch' and 'expect[s] LyFE to have the capacity to manufacture more than 1,200 CAR T-cell doses/year'
- Addition of transformed marginal zone B-cell lymphoma (tMZBCL) and transformed mantle cell lymphoma (tMCL) to NHL subtypes being pursued
- Reference to 'approximately 12,000 to 15,000 patients in the United States with LBC' (text appears truncated)
- Removed:
- Reference to 2024 Annual Report on Form 10-K filed March 11, 2025 (older filing used 2024 year-end data)
- Parenthetical reference '(also known as LYL314)' after rondecabtagene autoleucel in overview section
- Phrase 'chimeric antigen receptor (CAR) T-cell' expanded to 'CAR T-cell' only in newer version
- Phrase 'arm them with one or more of our innovative enhancements' changed to 'arm them with our innovative enhancements'
- Phrase 'delivering patients meaningfully improved outcomes' changed to 'delivering to patients meaningfully improved outcomes'
- Phrase 'CAR T cell products' changed to 'CAR T-cell product candidates'
- Description of PiNACLE as 'a pivotal clinical trial' without 'single-arm' or 'seamless expansion' language
- Reference to 'have announced the initiation of' PiNACLE-H2H (older phrasing)
- Phrase 'recently acquired' changed to specific date reference 'in November 2025'
- Reference to 'Innovative Cellular Therapeutics (ICT)' without mentioning Holdings Limited subsidiary
- Phrase 'refractory metastatic colorectal cancer (mCRC)' changed to 'refractory mCRC'
- Phrase 'in the hostile tumor microenvironment' changed to 'and cancer cell killing in the hostile tumor microenvironment'
- Paragraph describing 'research scientists' developing additional CAR T-cell candidates for solid tumors with anti-exhaustion technologies
- Phrase 'building and operating LyFE' and capacity statements in newer version's incorporated section
- Phrase 'establishing our intellectual property portfolio' changed to 'establishing and maintaining our intellectual property portfolio'
- Parenthetical '(also known as LYL314)' after ronde-cel in Pipeline Programs table heading
- Phrase 'relapsed and/or refractory' changed to 'relapsed/refractory (R/R)'
- Explanation of NHL vs. Hodgkin lymphoma differences in newer version
- Phrase 'The NHL subtypes we intend to initially pursue' changed to 'The NHL subtypes we are currently pursuing'
- Reference to 'tMZBCL and tMCL' added; older version stated 'tFL and Grade 3B follicular lymphoma (FL3B)'
- Phrase 'approximately 12,000 patients' changed to 'approximately 12,000 to 15,000 patients'
- Reworded:
- Change from 'Of the approximately 30,000 patients in the U.S. with LBCL, 40% to 50% are refractory to, or relapse following, first-line treatment and we estimate approximately 12,000 to 15,000 patients in the United States with LBC' (newer, text truncated) vs. older version 'Approximately 40% to 50% of patients with LBCL are refractory to, or relapse following, first-line treatment and we estimate approximately 12,000 patients in the United States with LBCL progress to 2L treatment'
- Shift from reference to 'third- or later-line (3L+) setting' to more detailed description of trial structure and timeline expectations
- Reordering and reorganization of information about LYL273 acquisition timing and clinical data
- Notes:
- Newer filing text appears truncated at end of excerpt ('approximately 12,000 to 15,000 patients in the United States with LBC' is incomplete)
- Older filing excerpt ends at page break; full comparison of subsequent sections not possible
- The removal of the paragraph about 'research scientists' developing additional CAR T-cell candidates may reflect organizational changes or section restructuring rather than substantive removal
Risk Factors
- Added:
- Added bullet point: 'If we are unable to successfully develop, manufacture and commercialize product candidates or experience significant delays in doing so, our business may be harmed.' (filed 2026-05-06)
- Added bullet point: 'Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.' (filed 2026-05-06)
- Added bullet point: 'If our clinical manufacturing facility in Bothell, Washington or any of our potential contract manufacturing organizations is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.' (filed 2026-05-06)
- Added bullet point: 'We do and will continue to or intend to rely on outside scientists and clinical trial investigators and their third-party research institutions for research and development and clinical testing of our product candidates. These scientists, investigators and institutions may have other commitments or conflicts of interest, which could limit our access to their expertise and harm our ability to leverage our technologies.' (filed 2026-05-06)
- Added bullet point: 'We are currently in clinical development of our product candidates, and our future success is dependent on the successful development and regulatory approval of our product candidates and any product candidates we acquire.' (filed 2026-05-06)
- Removed:
- Removed bullet point: 'We currently have no marketing, sales or distribution infrastructure, and we intend to either establish a sales and marketing infrastructure or outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us.' (filed 2025-11-12)
- Removed bullet point: 'We may rely on third parties to manufacture our product candidates, which could subject us to risks and delay or prevent our development and/or commercialization, if approved, of our product candidates.' (filed 2025-11-12)
- Removed bullet point: 'International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business, financial condition, results of operations and prospects.' (filed 2025-11-12)
- Removed bullet point: 'Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.' (filed 2025-11-12)
- Reworded:
- Reordered bullet points: 'We will require substantial additional capital...' moved from 4th to 2nd position (filed 2026-05-06 vs 2025-11-12)
- Reordered bullet points: 'We operate in a rapidly evolving field...' moved from 2nd to 4th position (filed 2026-05-06 vs 2025-11-12)
- Changed 'Our product candidates and technology platforms' to 'Our product candidates and technologies' (filed 2026-05-06 vs 2025-11-12)
- Changed 'technology platforms' to 'technologies' in related phrase (filed 2026-05-06 vs 2025-11-12)
- Removed phrase 'or finding suitable third-party manufacturing partners' from manufacturing facility bullet (filed 2026-05-06)
- Changed 'The manufacturing of cellular therapies' to 'The manufacturing of cell therapies' (filed 2026-05-06 vs 2025-11-12)
- Removed 'including risks associated with supply chain complexity related to patient materials' from manufacturing risks bullet (filed 2026-05-06)
- Changed 'We face substantial competition in rapidly changing industries' to 'We face substantial competition in a rapidly changing industry' (filed 2026-05-06 vs 2025-11-12)
- Shortened and simplified clinical trial results risk factor; removed phrase 'initial clinical results in a clinical trial may not be predictive of future results in the same clinical trial and results in one indication may not be predictive of results to be expected for the same product candidate in another indication' and 'Any product candidate we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval' (filed 2026-05-06)
- Changed 'Our cellular therapy' to 'Our cell therapy' (filed 2026-05-06 vs 2025-11-12)
- Changed reference from '2025 Annual Report' filed March 11, 2025 to reference to '2025 Annual Report' (filed 2026-05-06 vs 2025-11-12)
- Notes:
- The text provided is truncated at the end of both versions, cutting off the final bullet point about intellectual property protection. Full comparison of that item is not possible.
- Bullet point ordering changes are noted but the substantive content of reordered items remains functionally similar.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($6350) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 10 sells ($211301) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 15 sells ($251874) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-10. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LYEL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LYEL as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,149,195
- Reported value $16,146,190
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LYEL's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LYEL had 1,187,902 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
LYEL had 4.85% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.08 days to cover at the same settlement.
- Reported short interest (shares) 1,187,902
- Short interest (% of shares outstanding) 4.85%
- Prior settlement (shares) 1,131,628
- Reported change 4.97%
- Days to cover (reported) 12.08
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (Kite) (GILD)
- Bristol Myers Squibb
- Novartis (NVS)
- Legend Biotech (LEGN)
- Arcellx (ACLX)
- Innovative Cellular Therapeutics (ICT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LYEL vs…
LYELL IMMUNOPHARMA INC is found in…
Frequently asked questions
What does LYELL IMMUNOPHARMA INC (LYEL) do?
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation autologous chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies and solid tumors. The company engineers patient immune cells with proprietary enhancements, including anti-exhaustion technologies and manufacturing protocols that enrich for T-cells with stem-like features, to improve antitumor activity.
What sector is LYELL IMMUNOPHARMA INC (LYEL) in?
LYELL IMMUNOPHARMA INC (LYEL) is classified in the Health Care sector. Its industry is Biotechnology / Cell Therapy. It trades on NASDAQ.
Who are LYELL IMMUNOPHARMA INC's (LYEL) competitors?
Notable peers of LYELL IMMUNOPHARMA INC (LYEL) include Gilead Sciences (Kite), Bristol Myers Squibb, Novartis, Legend Biotech and Arcellx. This peer set is informational only — not financial advice.
Is LYELL IMMUNOPHARMA INC (LYEL) overbought or oversold right now?
LYELL IMMUNOPHARMA INC (LYEL) is currently in oversold territory (its 14-day RSI is 25, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LYEL come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.